Global Parenteral PrEP Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Parenteral PrEP market size was valued at US$ 299 million in 2025 and is forecast to a readjusted size of US$ 789 million by 2032 with a CAGR of 14.7% during review period.
Parenteral PrEP refers to HIV pre-exposure prophylaxis delivered via non-enteral routes—most commonly long-acting intramuscular injections, and in broader usage also implants or other sustained-release parenteral platforms—designed to maintain protective drug concentrations over extended intervals before potential HIV exposure occurs. In practice today, the term largely maps to long-acting injectable PrEP (e.g., long-acting cabotegravir), with the wider pipeline including implants and long-acting biologics. The central problem it addresses is not the pharmacologic efficacy of PrEP per se (daily oral PrEP is highly effective when taken as prescribed), but the implementation gap: adherence burden, missed doses, access continuity, and privacy/stigma concerns that can reduce real-world effectiveness; by shifting protection from “remember a pill every day” to “receive a dose every 1–2 months (or longer),” parenteral PrEP aims to deliver more consistent coverage and simplify prevention for people who struggle with, dislike, or cannot safely sustain oral regimens.In 2025, the global production capacity of parenteral PrEP reached 150,000 doses, while total sales amounted to 109,800 doses. The average selling price was USD 2,650 per dose, and the gross margin of manufacturers ranged between 60% and 70%.
The current parenteral PrEP market is in a transitional phase where clinical effectiveness is well established, but health systems and delivery models are still adapting to long-acting prevention. Acceptance among clinicians, public health authorities, and at-risk communities has grown steadily, particularly in populations where daily oral PrEP has faced adherence or continuity challenges. At the same time, the market shows a clear dual-track pattern: in higher-income settings, parenteral PrEP is typically integrated into structured medical care with an emphasis on monitoring and long-term management, while in resource-limited or high-incidence settings it is often embedded within public health programs aimed at reducing population-level transmission and stigma. As a result, uptake is shaped less by lack of interest than by variation in system readiness to support repeat dosing, follow-up, and logistics.
Looking ahead, the market is expected to evolve from reliance on a single dominant modality toward a landscape where multiple long-acting technologies coexist. Injectable approaches are likely to remain central in the near term, but innovation is increasingly focused on extending dosing intervals, offering alternative delivery formats, and pairing biomedical prevention with digital follow-up and community-based services. Parenteral PrEP is gradually being repositioned from a simple substitute for oral regimens to a flexible prevention option that can be tailored to different risk profiles, life circumstances, and care settings. Over time, competitive differentiation is likely to hinge on user experience and service integration, including convenience, discretion, and reduced long-term burden on both patients and providers.
The main drivers of this market include the persistent gap between proven efficacy and real-world adherence, growing policy emphasis on sustainable HIV prevention strategies, and ongoing advances in drug formulation and delivery science. At the same time, several constraints continue to shape adoption, such as dependence on healthcare infrastructure, the need for trained personnel and regular follow-up, social stigma and uneven awareness, and concerns around long-term safety or reversibility among certain users. The interaction of these forces suggests that growth in parenteral PrEP will be evolutionary rather than abrupt, unfolding alongside broader changes in health policy, service delivery, and social acceptance rather than through rapid, uniform expansion.
This report is a detailed and comprehensive analysis for global Parenteral PrEP market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Parenteral PrEP market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Parenteral PrEP market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Parenteral PrEP market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Parenteral PrEP market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Parenteral PrEP
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Parenteral PrEP market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, ViiV Healthcare, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Parenteral PrEP market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Cabotegravir
Lenacapavir
Other
Market segment by Dosing Interval
Short-interval Injections
Monthly Injections
Quarterly Injections
Market segment by Drug Properties
Original Drug
Generic Drug
Market segment by Application
Subcutaneous Use
Intramuscular Use
Major players covered
Gilead Sciences
ViiV Healthcare
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Parenteral PrEP product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Parenteral PrEP, with price, sales quantity, revenue, and global market share of Parenteral PrEP from 2021 to 2026.
Chapter 3, the Parenteral PrEP competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Parenteral PrEP breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Parenteral PrEP market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Parenteral PrEP.
Chapter 14 and 15, to describe Parenteral PrEP sales channel, distributors, customers, research findings and conclusion.